Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYHA1807 Phase I in Extensive-Stage Small Cell Lung Cancer
NCT04404543Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jun 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of SYHA1807 in small cell lung cancer (SCLC) (2 cohorts), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Number of Participants With Adverse Events, Number of Participants With Serious Adverse Events and 5 more. Status: unknown.
02
Drugs
SYHA1807
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04404543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04404543.